LOGIN / MY PROFILE / LOGOUT
Please remember registration is not considered complete until payment has been received by the BBANYS Central Office. Upon receipt of payment, you will receive a confirmation email. If you have any questions, please contact email@example.com.
Wednesday, September 8, 2021 / 3:00 PM - 4:00 PM EDT
Title: Blood Product Selection for Transfusion of Bone Marrow Transplant Patients
Ljiljana Vasovic, MD
Associate Director of Cellular Therapy & Assistant Director of Transfusion Medicine
New York Presbyterian Hospital-Weill Cornell Campus
Chief of Clinical Pathology and Transfusion Medicine
New York-Presbyterian/Lower Manhattan Hospital
Bio: Dr. Vasovic is Chief of Clinical Pathology and Transfusion Medicine at New York-Presbyterian/Lower Manhattan, Associate Medical Director of the Cellular Therapy Laboratory at New York-Presbyterian Hospital, and is Assistant Professor of Pathology and Laboratory Medicine, Weill Cornell Medicine. Dr. Vasovic received a Medical Degree from the University of Belgrade, School of Medicine. She completed an immunology research fellowship at Memorial Sloan Kettering Cancer Center, a residency in Pathology at Lenox Hill Hospital, New York University, a Hematopathology fellowship at Albert Einstein College of Medicine and Transfusion Medicine Fellowship at Harvard Medical School, Joint Program in Transfusion Medicine. Dr. Vasovic's primary research interests include optimizing stem cell transplants procedures for the treatment of hematologic malignancies and enhancing quality assurance programs for cellular therapy laboratories.
Abstract: Appropriate therapeutic and supportive transfusion management of ABO, as well as non-ABO, blood group incompatible Hematopoietic progenitor cell transplantation (HPCT) recipients, can become a critical and challenging task during the post-transplantation time period. 20% to 50% of HPCT are ABO incompatible. Hemolysis is a cardinal symptom of blood group incompatibility. Immediate hemolysis is predominantly due to a high titer of anti-ABO isohemagglutinins. Delayed hemolysis in major incompatible transplants presents as delayed erythroid engraftment or pure red cell aplasia. Delayed hemolysis in minor incompatible transplants usually presents as transient hemolysis due to an expansion of passenger lymphocytes. Transfusion of blood components compatible with both the donor and recipient should be considered. Blood product selection will be discussed supported by case presentations.
To receive member pricing, be sure to sign in.
BLOOD BANKS ASSOCIATION OF NEW YORK STATECOPYRIGHT © 2023
CONTACT USPhone: 866-397-8883
Fax: 651-317-8048Email: firstname.lastname@example.org
2345 Rice Street, Suite 220St. Paul, MN 55113